THE WELCH COMPANY
440 Davis Court #1602
San Francisco, CA 94111-2496
415 781 5700
rodwelch@pacbell.net
S U M M A R Y
DIARY: September 11, 2008 08:00 AM Thursday;
Rod Welch
Millie 4th treatment 7th cycle cetuximab Carboplatin 4th relapse IBC.
1...Summary/Objective
...Taxotere Capecitabine 2nd Relapse IBC Treatment After Mastectomy
...Cetuxiab Alone Clinical Study
...Cetuxiab 81 and Carboplatin 14 Treatments Clinical Study 2nd Arm
2...Schedule Weekly Treatments Continue on Thursdays
3...Labs Blood Test
4...NEUTS 1.43 Decrease 4th Week Chemotherapy Bye Week
5...Chemotherapy Carboplatin Bye Week Blood Counts Good for Treatment
6...Blood Counts Decrease Still Good Chemotherapy Carboplatin Bye Week
7...Neutropenia Case Study Missed Chemotherapy and Neupogen Treatments
8...Case Study Neutropenia 28 Treatments Neupogen Missed 4 Chemotherapy
9...Neupogen 28 Treatments Neutropenia Missed Carboplatin 4 Treatments
10...Neupogen Side Effects Case Study Indicates Good Tolerance
11...Side Effects Neupogen Treatments Continue Mild Tolerance Acceptable
12...CT Test Work Plan Arrangements to Be Prepared on 080911
13...Huber Needle Configured for Use Later at Kaiser for CT Test
..............
Click here to comment!
CONTACTS
SUBJECTS
Cetuximab Carboplatin Clinical Study 2nd Arm 7th Cycle 1st Treatment
1003 -
1003 - ..
1004 - Summary/Objective
1005 -
100501 - Follow up ref SDS G7 0000. ref SDS G2 0000.
100502 -
100503 -
100504 -
100505 -
100506 -
100507 -
100508 -
100510 - ..
1006 -
1007 -
1008 - Progress
1009 -
100901 - Background on Millie's treatment in the clinical study is reported on
100902 - 080508. ref SDS 99 TZ8I
100904 - ..
100905 - Taxotere Capecitabine 2nd Relapse IBC Treatment After Mastectomy
100906 -
100907 - Follow up ref SDS G7 X33O, ref SDS G2 X33O.
100908 -
100909 - Millie had left mastectomy surgery on 051021. ref SDS 5 EG5L
100910 - Biopsy at that time reported no findings of cancer. Approximately 8
100911 - months later on 060707 the doctor diagnosed IBC relapse and
100912 - prescribed treatment with capecitabine and Taxotere, which had been
100913 - effective in 2005 completely eliminating signs of IBC disease.
100914 - ref SDS 6 PF3O
100915 -
100916 - 1. Cycle 09 and 01 ................... 060721, ref SDS 7 407N
100917 - 2. Cycle 10 and 02 ................... 060814, ref SDS 9 LY6O
100918 - 3. Cycle 11 and 03 ................... 060908, ref SDS 9 407N
100919 - 4. Cycle 12 and 04 ................... 060929, ref SDS 9 407N
100920 - 5. Cycle 13 and 05 ................... 061020, ref SDS 10 407N
100921 - 6. Cycle 14 and 06 ................... 061110, ref SDS 11 407N
100922 - 7. Cycle 15 and 07 ................... 061201, ref SDS 12 407N
100924 - ..
100925 - Cetuxiab Alone Clinical Study
100926 -
100927 - Follow up ref SDS G7 356I, ref SDS G2 356I.
100928 -
100929 - After 7 cycles of treatment in 2006, the doctor diagnosed IBC
100930 - disease was progressing, and so made referral to UCSF for treatment
100931 - in a clinical study of Cetuximab and Carboplatin. Millie was
100932 - randominzed for treatment with Cetuximab alone, and began weekly
100933 - treatments at UCSF on 080201.
100935 - ..
100936 - Total Cetuximab
100937 - 8. Cycle 01 and 08 and 01 01.......... 070201, ref SDS 14 SG8I
100938 - 9. Cycle 01 and 08 and 02 02.......... 070208, ref SDS 15 SG8I
100939 - 10. Cycle 01 and 08 and 03 03.......... 070215, ref SDS 16 SG8I
100940 - 11. Cycle 01 and 08 and 04 04.......... 070222, ref SDS 17 SG8I
100941 - 12. Cycle 02 and 09 and 01 05.......... 070301, ref SDS 19 SG8I
100942 - 13. Cycle 02 and 09 and 02 06.......... 070308, ref SDS 21 7T3H
100943 - 14. Cycle 02 and 09 and 03 07.......... 070315, ref SDS 22 7T3H
100944 - 15. Cycle 02 and 09 and 04 08.......... 070322, ref SDS 23 7T3H
100945 - 16. Cycle 03 and 10 and 01 09.......... 070329, ref SDS 24 7T3H
100946 - 17. Cycle 03 and 10 and 02 10.......... 070405, ref SDS 25 7T3H
100947 - 18. Cycle 03 and 10 and 03 11.......... 070412, ref SDS 26 7T3H
100948 - 19. Cycle 03 and 10 and 04 12.......... 070419, ref SDS 27 7T3H
100949 - 20. Cycle 04 and 11 and 01 13.......... 070426, ref SDS 28 7T3H
100950 - 21. Cycle 04 and 11 and 02 14.......... 070503, ref SDS 29 7T3H
100951 - 22. Cycle 04 and 11 and 03 15.......... 070510, ref SDS 30 7T3H
100952 - 23. Cycle 04 and 11 and 04 16.......... 070517, ref SDS 31 7T3H
100953 - 24. Cycle 05 and 12 and 01 17.......... 070524, ref SDS 32 7T3H
100954 - 25. Cycle 05 and 12 and 02 18.......... 070531, ref SDS 33 7T3H
100955 - 26. Cycle 05 and 12 and 03 19.......... 070607, ref SDS 34 7T3H
100956 - 27. Cycle 05 and 12 and 04 20.......... 070614, ref SDS 35 0001
100957 - 28. Cycle 06 and 13 and 01 21.......... 070621, ref SDS 36 0001
100958 - 29. Cycle 06 and 13 and 02 22.......... 070628, ref SDS 37 0001
100959 - 30. Cycle 06 and 13 and 03 23.......... 070705, ref SDS 38 0001
100960 - 31. Cycle 06 and 13 and 04 24.......... 070712, ref SDS 38 0001
100961 - 32. Cycle 07 and 14 and 01 25.......... 070719, ref SDS 39 0001
100962 - 33. Cycle 07 and 14 and 02 26.......... 070726, ref SDS 37 0001
100963 - 34. Cycle 07 and 14 and 03 27.......... 070802, ref SDS 38 0001
100964 - 35. Cycle 07 and 14 and 04 28.......... 070809, ref SDS 40 0001
100965 - 36. Cycle 08 and 15 and 01 29.......... 070816, ref SDS 41 0001
100966 - 37. Cycle 08 and 15 and 02 30.......... 070823, ref SDS 42 0001
100967 - 38. Cycle 08 and 15 and 03 31.......... 070830, ref SDS 42 0001
100968 - 39. Cycle 08 and 15 and 04 32.......... 070906, ref SDS 43 0001
100969 - 40. Cycle 09 and 16 and 01 33.......... 070920, ref SDS 44 0001
100970 - 41. Cycle 09 and 16 and 02 34.......... 070927, ref SDS 45 0001
100971 - 42. Cycle 09 and 16 and 03 35.......... 071004, ref SDS 46 0001
100972 - 43. Cycle 09 and 16 and 04 36.......... 071011, ref SDS 47 0001
100973 - 44. Cycle 10 and 17 and 01 37.......... 071018, ref SDS 48 0001
100974 - 45. Cycle 10 and 17 and 02 38.......... 071025, ref SDS 49 0001
100975 - 46. Cycle 10 and 17 and 03 39.......... 071101, ref SDS 35 0001
100976 - 47. Cycle 10 and 17 and 04 40.......... 071108, ref SDS 50 0001
100977 - 48. Cycle 11 and 18 and 01 41.......... 071115, ref SDS 51 0001
100978 - 49. Cycle 11 and 18 and 02 42.......... 071122, ref SDS 37 0001
100979 - 50. Cycle 11 and 18 and 03 43.......... 071129, ref SDS 54 0001
100980 - 51. Cycle 11 and 18 and 04 44.......... 071206, ref SDS 55 0001
100981 - 52. Cycle 12 and 19 and 01 45.......... 071213, ref SDS 58 0001
100982 - 53. Cycle 12 and 19 and 02 46.......... 071220, ref SDS 61 0001
100983 - 54. Cycle 12 and 19 and 03 47.......... 071227, ref SDS 62 0001
100984 - 55. Cycle 12 and 19 and 04 48.......... 080103, ref SDS 63 0001
100985 - 56. Cycle 13 and 20 and 01 49.......... 080110, ref SDS 66 0001
100986 - 57. Cycle 13 and 20 and 02 50.......... 080117, ref SDS 67 0001
100987 - 58. Cycle 13 and 20 and 03 51.......... 080124, ref SDS 68 0001
100988 - 59. Cycle 13 and 20 and 04 52.......... 080131, ref SDS 70 0001
100989 - 60. Cycle 14 and 21 and 01 53.......... 080207, ref SDS 74 0001
100990 - 61. Cycle 14 and 21 and 02 54.......... 080214, ref SDS 75 0001
100991 - 62. Cycle 14 and 21 and 03 55.......... 080221, ref SDS 38 0001
100992 - 63. Cycle 14 and 21 and 04 56.......... 080228, ref SDS 80 0001
100993 - 64. Cycle 15 and 22 and 01 57 01 00... 080306, ref SDS 83 TZ8I
100995 - ..
100996 - Cetuxiab 81 and Carboplatin 14 Treatments Clinical Study 2nd Arm
100997 -
100998 - Follow up ref SDS G7 5B6J, ref SDS G2 5B6J.
100999 -
101000 - On 080207 doctor reports IBC may be spreading. ref SDS 73 GH5H
101001 - Follow up examination on 080219 Doctor Rugo diagnosed progression of
101002 - disease. ref SDS 93 3J4I Photographs show spread of IBC rash, UCSF
101003 - prescribed treatment under the 2nd Arm of the study so that Millie
101004 - now gets weekly treatment with cetuximab and with Carboplatin 3
101005 - weeks of each 4 week cycle.
101006 -
101007 - 2nd
101008 - Arm Cetuximab Carboplatin
101009 - 65. Cycle 01 15 and 22 and 02 58 02 01... 080313, ref SDS 84 TZ8I
101010 - 66. Cycle 01 15 and 22 and 03 59 03 01... 080320, ref SDS 85 TZ8I
101011 - 67. Cycle 01 15 and 22 and 04 60 04 01... 080327, ref SDS 86 TZ8I
101012 - 68. Cycle 02 16 and 23 and 01 61 05 02... 080403, ref SDS 87 TZ8I
101013 - 69. Cycle 02 16 and 23 and 02 62 06 03... 080410, ref SDS 90 TZ8I
101014 - 70. Cycle 02 16 and 23 and 03 63 07 03... 080417, ref SDS 92 TZ8I
101015 - 71. Cycle 02 16 and 23 and 04 64 08 03... 080424, ref SDS 94 TZ8I
101016 - 72. Cycle 03 17 and 24 and 01 65 09 04... 080501, ref SDS 97 5B6J
101017 - 73. Cycle 03 17 and 24 and 02 66 10 05... 080508, ref SDS 99 5B6J
101018 - 74. Cycle 03 17 and 24 and 03 67 11 05... 080515, ref SDS A0 5B6J
101019 - 75. Cycle 03 17 and 24 and 04 68 12 05... 080522, ref SDS A1 5B6J
101020 - 76. Cycle 04 18 and 25 and 01 69 13 06... 080529, ref SDS A4 5B6J
101021 - 77. Cycle 04 18 and 25 and 02 70 14 07... 080605, ref SDS A5 5B6J
101022 - 78. Cycle 04 18 and 25 and 03 71 15 08... 080612, ref SDS A8 5B6J
101023 - 79. Cycle 04 18 and 25 and 04 72 16 08... 080619, ref SDS B1 5B6J
101024 - 80. Cycle 05 19 and 26 and 01 73 17 09... 080626, ref SDS B6 5B6J
101025 - 81. Cycle 05 19 and 26 and 02 74 18 10... 080703, ref SDS C1 5B6J
101026 - 82. Cycle 05 19 and 26 and 03 75 19 11... 080710, ref SDS C4 5B6J
101027 - 83. Cycle 05 19 and 26 and 04 76 20 11... 080717, ref SDS D0 5B6J
101028 - 84. Cycle 06 20 and 27 and 01 77 21 12... 080724, ref SDS D7 5B6J
101029 - 85. Cycle 06 20 and 27 and 02 78 22 13... 080731, ref SDS E1 5B6J
101030 - 86. Cycle 06 20 and 27 and 03 79 23 14... 080807, ref SDS E7 5B6J
101031 - 87. Cycle 06 20 and 27 and 04 80 24 14... 080814, ref SDS F3 5B6J
101032 - 88. Cycle 07 21 and 28 and 01 81 25 14... 080821, ref SDS F6 5B6J
101033 - 89. Cycle 07 21 and 28 and 02 82 26 15... 080828, ref SDS G2 5B6J
101034 - 90. Cycle 07 21 and 28 and 03 83 27 16... 080904, ref SDS G7 5B6J
101035 - 91. Cycle 07 21 and 28 and 04 84 28 16... 080911, ref SDS 0 5B6J
101037 - ..
101038 - Today is the 4th treatment of the 7th cycle with cetuximab and
101039 - Carboplatin together. This is the 28th treatment overall with
101040 - cetuximab on the 2nd arm of the clinical study, but is only the 16th
101041 - treatment with Carboplatin due to low blood counts. Millie missed the
101042 - 1st treatment of the cycle on 080821. ref SDS F6 V94O
101043 -
101044 -
101045 -
101046 -
101047 -
1011 -
SUBJECTS
Default Null Subject Account for Blank Record
1703 -
170401 - ..
170402 - Schedule Weekly Treatments Continue on Thursdays
170403 -
170404 - Follow up ref SDS G7 1K7H, ref SDS G2 1K7H.
170405 -
170406 - The current schedule is listed on 080904. ref SDS G7 PN6F
170408 - ..
170409 - The schedule for Neupogen is listed on 080905. ref SDS G8 WJ4O
170410 -
170411 -
170412 -
170413 -
1705 -
SUBJECTS
Blood Tests Labs Infusion Clinic Evaluate Safe Chemotherapy 1st Trea
2503 -
2504 - 0750
250501 - ..
250502 - Labs Blood Test
250503 -
250504 - Follow up ref SDS G7 FW5N, ref SDS G2 FW5N.
250505 -
250506 - Adding Carboplatin to the treatment protocol now requires weekly blood
250507 - tests to determine if the immune system is strong enough for safe
250508 - chemotherapy treatment, reported on 070201, ref SDS 14 XR40, and
250509 - citing the clinical study protocol received from UCSF on 070116.
250510 - ref SDS 13 5U7Z
250512 - ..
250513 - Diane is the nurse today, because Catherine is the supervisor today
250514 - for the Infusion Clinic.
250516 - ..
250517 - Diane accessed the Power Port for Millie's blood draw and treatment.
250518 - She used a Huber needle that supports high pressure injections needed
250519 - for Millie to get a CT test later today at Kaiser in Oakland, per
250520 - planning below. ref SDS 0 V64G
250521 -
250522 -
250523 -
250525 - ..
2506 -
2507 -
2508 - 1022
2509 -
250901 - During treatment, Catherine submitted results of the test for the 4th
250902 - treatment of the 7th cycle. Scope is reduced from starting cycle 7 on
250903 - 080821, ref SDS F6 075H, and is the same for the 3rd treatment of the
250904 - 7th cycle. ref SDS G7 075H
250905 -
250920 - ..
250921 - Log#: 080911 08:15
250922 - <----------------------- U C S F -----------------------> <------------- Kaiser -------------->
250923 - Type Results Units Normal ACRO Type Units Normal
250924 - ..
250925 - CBC with DIFF & PLT CT CBCD
250926 - ..
250927 - WBC COUNT 3.6 x10E9/L 3.4 - 10 WBC WBC x10-3 K/uL 3.4 - 10.0
250928 - RBC COUNT L 3.79 x10E12/L 4 - 5.2 RBC RBC x10-6 M/uL 3.60 - 5.70
250929 - HEMOGLOBIN 12.7 g/dL 12 - 15.5 HGB Hemoglobin g/dL 11.5 - 15.0
250930 - HEMATOCRIT 37.4 PERCENT 36 - 46 HCT Hematocrit % 34.0 - 46.0
250931 - MCV 99 fL 80 - 100 MCV MCV fL 80.0 - 100.0
250932 - MCH H 33.6 pg 26 - 34 MCH
250933 - MCHC 34.1 g/dL 31 - 36 MCHC
250934 - PLATELETS 216 x10E9/L 140 - 450 PLT Plt x10-3 K/uL 140 - 400
250935 -
250936 - Performed at Mt Zion Clinic Lab, 1600 Divisadero, San
250937 - Francisco, CA 94115
250938 - ..
250939 - (NEUTS x 1000 = ANC for Kaiser)
250940 - NEUTS 1.43 x10E9/L 1.8 - 6.8 N-A ANC 1500
250941 - Neutrophils Not Reported Neutrophils % 50 - 70
250943 - ..
250944 - LYMPHS 1.60 x10E9/L 0.9 - 2.9 L-A Lymphocytes % 20 - 50
250945 - MONOS 0.28 x10E9/L 0.2 - 0.8 M-A Monocyte % 0 - 11
250946 - EOS 0.11 x10E9/L 0 - 0.4 E-A Esoinophils % 1 - 5
250947 - BASOS 0.05 x10E9/L 0 - 0.1 B-A Basophil % 0 - 2
250948 - LUC/ATYP LYMPHS 0.10 x10E9/L 0.0 - 0.2 LALA
250950 - ..
250951 - <----------------------- U C S F -----------------------> <------------- Kaiser -------------->
250952 - Type Results Units Normal ACRO Type Units Normal
250953 - ELECTROLYTE PANEL LYTE
250954 - ..
250955 - MAGNESIUM 1.9 mg/dL 1.8 - 2.3 MG Magnesium mg/dL 1.6 - 2.3
250957 - ..
250958 - CREAT with eGFR
250959 - CREATININE L 0.41 mg/dL 0.42 - 1.06 CR Creatinine mg/dL 0.6 - 1.2
250960 -
250961 - Note: Creatinine assay changed to IDMS standardization on
250962 - February 4, 2008 causing decrease in results of approximately
250963 - 0.09 mg/dL
250965 - ..
250966 - eGFR if Caucasian >60 mL/min GFRC
250967 - eGFR if African Amer >60 mL/min GFRA
250968 -
250969 - eGFR corrected for 1.73 sq meters of body surface area
250970 - Note: eGFR is only an estimation. Please see online Lab Manual
250971 - for potential limitations.
250972 - Performed at Mt Zion Clin Lab, 1600 Divisadero, San Francisco,
250973 - CA 94115
250974 -
250975 -
250976 -
250977 -
2510 -
SUBJECTS
Absolute Neutrophils Count ANC 6850 Above 1500 NEUTS 6.85 Above 1.5
3403 -
340401 - ..
340402 - NEUTS 1.43 Decrease 4th Week Chemotherapy Bye Week
340403 - Chemotherapy Carboplatin Bye Week Blood Counts Good for Treatment
340404 - Blood Counts Decrease Still Good Chemotherapy Carboplatin Bye Week
340405 -
340406 - Follow up ref SDS G7 PU6K, ref SDS G2 PU6K.
340407 -
340408 - Blood counts decreased this week, shown by the Lab report today with
340409 - NEUTS 1.43, ref SDS 0 QY6H, compared with NEUTS 1.99 last week on
340410 - 080904, ref SDS G7 QY6H This is slightly below UCSF standard of 1.5
340411 - for Millie to safely get chemotherapy treatment. Since today is the
340412 - 4th week in the cycle, this is a bye week for chemotherapy. Millie
340413 - had 2 Neupogen treatments last week at Kaiser according to the regular
340414 - schedule on 080905. ref SDS G8 WJ4O
340416 - ..
340417 - NEUTS dropping today below the standard for safe treatment of
340418 - chemotherapy supports getting Neupogen at Kaiser tomorrow and on
340419 - 080913, under Doctor Rugo's analysis on 080821, ref SDS F5 4B95, to
340420 - avoid problems next week that prevented getting chemotherapy treatment
340421 - starting the cycle on 080821 ref SDS F6 PU6K, due to not getting
340422 - Neupogen the week before on 080814. ref SDS F4 UK3K
340423 -
340424 - [On 080918 with 2 Neupogen treatments Millie's blood counts
340425 - increased enough to avoid missing another chemotherapy
340426 - treatment. ref SDS G9 PU6K
340428 - ..
340429 - [On 080918 case study shows 2 Neupogen treatments on each of
340430 - all 4-weeks in the chemotherapy cycle avoids missing
340431 - chemotherapy treatments. ref SDS G9 OK67
340432 -
340433 -
340434 -
340435 -
3405 -
SUBJECTS
Default Null Subject Account for Blank Record
3503 -
350401 - ..
350402 - Neutropenia Case Study Missed Chemotherapy and Neupogen Treatments
350403 - Case Study Neutropenia 28 Treatments Neupogen Missed 4 Chemotherapy
350404 - Neupogen 28 Treatments Neutropenia Missed Carboplatin 4 Treatments
350405 -
350406 - Follow up ref SDS G7 8O7I, ref SDS G2 8O7I.
350407 -
350408 - Case study on 060809 shows Millie has often received chemotherapy when
350409 - blood counts are below the standard for safe treatments, and on some
350410 - occassions has received Neupogen to increase blood counts. ref SDS 8
350411 - HV45 Today is not an issue, because the 4th treatment is a bye week
350412 - in the cycle.
350414 - ..
350415 - Research on neutropenia was reported on 070301, ref SDS 18 O59H, when
350416 - Doctor Rugo was concerned about holding blood counts with weekly
350417 - Carboplatin treatments. ref SDS 18 VF6O
350419 - ..
350420 - Millie has received 30 Neupogen treatments, and missed 4 chemotherapy
350421 - treatments due to rising neutropenia, and so has received only 16 of
350422 - 20 total treatments prescribed with Carboplatin, since starting the
350423 - 2nd arm of the clinical study on 080306...
350425 - ..
350426 - Neupogen Carboplatin
350427 - Date NEUTS Cur Totl Cycl Trm Rcvd Missed
350428 -
350429 - 080911 1.43 2 30 7 4 16.......... ref SDS 0 QY6H
350430 - 080904 1.99 2 28 7 3 16.......... ref SDS G7 QY6H
350431 - 080828 3.09 2 26 7 2 15.......... ref SDS G2 QY6H
350432 - 080821 0.99 2 24 7 1 14 4... ref SDS F6 QY6H
350433 - 080814 1.37 0 22 6 4 14.......... ref SDS F3 QY6H
350434 - 080807 2.41 2 22 6 3 14.......... ref SDS E7 QY6H
350435 - 080731 1.92 2 20 6 2 13.......... ref SDS E1 QY6H
350436 - 080724 2.32 2 18 6 1 12.......... ref SDS D7 QY6H
350437 - 080717 2.47 1 16 5 4 11.......... ref SDS D0 QY6H
350439 - ..
350440 - On 080718 2 Neupogen treatments were cancelled at Kaiser,
350441 - ref SDS D1 9W9I, because the day before at UCSF on 080717
350442 - NUETS were high, and there was no Carboplatin chemotherapy
350443 - treatment given for the 4th week in the cycle on 080717.
350445 - ..
350446 - On 080719 the day after CT testing, Millie went to Kaiser
350447 - and received 1 Neupogen treatment as a precaution ordered
350448 - by Kaiser after bleeding trauma during failed CT test using
350449 - the Power Port the day before on 080718. ref SDS D2 SR37
350451 - ..
350452 - Neupogen Carboplatin
350453 - Date NEUTS Cur Totl Cycl Trm Rcvd Missed
350454 -
350455 - 080710 5.12 2 15 5 3 11......... ref SDS C4 QY6H
350456 - 080703 2.90 2 13 5 2 10......... ref SDS C1 QY6H
350457 - 080626 1.80 2 11 5 1 09......... ref SDS B6 QY6H
350458 - 080619 0.74 1 9 4 4 08......... ref SDS B1 QY6H
350459 - 080612 3.77 2 8 4 3 08......... ref SDS A8 QY6H
350461 - ..
350462 - On 080609 Kaiser orders 2 Neupogen treatments per week in
350463 - Infusion Clinic, ref SDS A7 IL6I, for UCSF prescription in
350464 - Chemo Orders on 080529, ref SDS A7 L16I, which were
350465 - received on 080605. ref SDS A5 JN38
350467 - ..
350468 - Neupogen Carboplatin
350469 - Date NEUTS Cur Totl Cycl Trm Rcvd Missed
350470 -
350471 - 080605 1.55 2 6 4 2 07......... ref SDS A5 QY6H
350472 - 080529 2.26 1 4 4 1 06......... ref SDS A4 QY6H
350473 - 080522 0.96 0 3 4 05......... ref SDS A1 QY6H
350474 - 080515 1.21 0 3 3 05 3.. ref SDS A0 QY6H
350475 - 080508 5.41 1 3 3 2 05......... ref SDS 99 QY6H
350476 - 080501 1.34 1 2 3 1 04......... ref SDS 97 QY6H
350477 - 080424 1.34 0 2 4 03......... ref SDS 94 QY6H
350478 - 080417 0.95 0 2 3 03 2.. ref SDS 92 QY6H
350479 - 080410 6.85 0 2 2 03......... ref SDS 90 QY6H
350480 - 080403 1.34 1 1 2 1 02......... ref SDS 87 QY6H
350481 - 080327 2.30 0 1 4 01......... ref SDS 86 QY6H
350482 - 080320 1.28 0 1 3 01 1.. ref SDS 85 QY6H
350483 - 080313 2.05 0 1 2 01......... ref SDS 84 QY6H
350484 - 080306 1.75 0 1 1 00......... ref SDS 83 QY6H
350485 -
350486 -
350487 -
3505 -
SUBJECTS
Default Null Subject Account for Blank Record
3603 -
360401 - ..
360402 - Neupogen Side Effects Case Study Indicates Good Tolerance
360403 - Side Effects Neupogen Treatments Continue Mild Tolerance Acceptable
360404 -
360405 - Follow up ref SDS G7 SB8I, ref SDS G2 SB8I.
360406 -
360407 - Last weekend, Millie reported severe, momentary back pain on two
360408 - consecutive days. ref SDS G5 VP4H
360410 - ..
360411 - Side effects of Neupogen may be lessening, reported on...
360412 -
360413 - 080831................, ref SDS G5 VP4H
360414 - 080825................, ref SDS F8 9W9I
360415 - 080810................, ref SDS F1 9W9I
360416 - 080803................, ref SDS E2 9W9I
360417 - 080726................, ref SDS D9 9W9I
360418 - 080721................, ref SDS D4 9W9I
360419 - 080713................, ref SDS C7 RM94
360420 - 080629................, ref SDS C0 6Q5J
360421 - 080628................, ref SDS B8 6Q5J
360422 -
360423 - ...suggesting increased ability to tolerate 2 Neupogen treatments per
360424 - week.
360425 -
360427 - ..
360428 - Since today is the 4th week in the cycle, Millie gets only cetuximab,
360429 - as called out in the doctor's Chemotherapy Order for cetuximab
360430 - reported on 080821, ref SDS F6 SH76, and also the Chemotherapy Order
360431 - for Carboplatin chemotherapy. ref SDS F6 PVVV
360432 -
360433 -
360434 -
360435 -
360436 -
3605 -
SUBJECTS
Default Null Subject Account for Blank Record
3703 -
370401 - ..
370402 - CT Test Work Plan Arrangements to Be Prepared on 080911
370403 -
370404 - Follow up ref SDS G7 V64G.
370405 -
370406 - Visited with Catherine and Diane.
370408 - ..
370409 - Catherine advised today that she received Millie's letter to the
370410 - medical team on 080903, ref SDS G6 IO5T She and Diane discussed the
370411 - specification for the Huber needle, which was submitted to Millie at
370412 - UCSF on 080724, ref SDS D7 MV7Y, and which Diane used today for
370413 - Millie's treatment, per above, ref SDS 0 TL4N, and which will be used
370414 - again later today for Millie's CT test at Kaiser in Oakland scheduled
370415 - for 1330. This follows up Catherine's plan last week on 080904 to
370416 - verify the Huber needle used for treatment today at UCSF supports high
370417 - pressure injection of contrast medium for Millie's CT test.
370418 - ref SDS G7 V64G
370419 -
370421 - ..
3705 -
3706 -
3707 - 1115
3708 -
370801 - Huber Needle Configured for Use Later at Kaiser for CT Test
370802 -
370803 - When treatment ended today, Diane flushed the port with saline and
370804 - Heprin required by protocol for standard of care. Rather than remove
370805 - the Huber needle, she taped it to Millie's chest for use later today
370806 - at Kaiser in Oakland. Diane used a procedure (except without
370807 - stitches) similar to that which the doctor used at Kaiser on 080708
370808 - accessing the port for use 2 days later at UCSF, reported on 080710.
370809 - ref SDS C4 I27G
370811 - ..
370812 - When Millie's treatment ended, Catherine submitted a copy of the
370813 - product specification for the Lifeguard Safety Huber needle which
370814 - Millie can give to the CT technologist at Kaiser in Oakland for the
370815 - purpose of avoiding confusion about meeting requirements for high
370816 - pressure injection of contrast medium performing CT tests. As noted
370817 - in the product specification received from UCSF on 080724, the
370818 - documents expressly states for CT tests. ref SDS D7 N79U Catherine
370819 - was aware that Millie had previously submitted a letter on 080903
370820 - transmitting this product specification, ref SDS G6 IO6R, to the
370821 - medical team for distribution to the Oakland CT Department, and
370822 - including Bard manufacturing for purposes of verifying compatibility
370823 - with Power Port requirements in the Instructions for Use.
370825 - ..
370826 - After Millie's CT test at Oakland, a nurse in the Infusion Clinic at
370827 - Oakland will remove the Huber needle, per planning in Millie's letter
370828 - to the medical team on 080903. ref SDS G6 IO5T
370829 -
370830 -
370831 -
370832 -
370833 -
370834 -
370835 -
370836 -
370837 -
3709 -